These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33837198)

  • 1. SLPI is a critical mediator that controls PTH-induced bone formation.
    Morimoto A; Kikuta J; Nishikawa K; Sudo T; Uenaka M; Furuya M; Hasegawa T; Hashimoto K; Tsukazaki H; Seno S; Nakamura A; Okuzaki D; Sugihara F; Ninomiya A; Yoshimura T; Takao-Kawabata R; Matsuda H; Ishii M
    Nat Commun; 2021 Apr; 12(1):2136. PubMed ID: 33837198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Notch Ligand Jagged1 Regulates the Osteoblastic Lineage by Maintaining the Osteoprogenitor Pool.
    Lawal RA; Zhou X; Batey K; Hoffman CM; Georger MA; Radtke F; Hilton MJ; Xing L; Frisch BJ; Calvi LM
    J Bone Miner Res; 2017 Jun; 32(6):1320-1331. PubMed ID: 28277610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of bone sialoprotein (BSP) impairs primary bone formation and resorption: the marrow ablation model under PTH challenge.
    Wade-Gueye NM; Boudiffa M; Vanden-Bossche A; Laroche N; Aubin JE; Vico L; Lafage-Proust MH; Malaval L
    Bone; 2012 May; 50(5):1064-73. PubMed ID: 22586700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of TIMP-1 in osteoblasts increases the anabolic response to PTH.
    Merciris D; Schiltz C; Legoupil N; Marty-Morieux C; de Vernejoul MC; Geoffroy V
    Bone; 2007 Jan; 40(1):75-83. PubMed ID: 16949899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitavastatin prevents ovariectomy-induced osteoporosis by regulating osteoclastic resorption and osteoblastic formation.
    Cheon YH; Lee CH; Kim S; Park GD; Kwak SC; Cho HJ; Kim JY; Lee MS
    Biomed Pharmacother; 2021 Jul; 139():111697. PubMed ID: 34243614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
    Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
    J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
    Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
    Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone temporal effects on bone formation and resorption.
    Kroll MH
    Bull Math Biol; 2000 Jan; 62(1):163-88. PubMed ID: 10824426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
    Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
    J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postnatal deletion of β-catenin in osterix-expressing cells is necessary for bone growth and intermittent PTH-induced bone gain.
    Yu C; Xuan M; Zhang M; Yao Q; Zhang K; Zhang X; Guo J; Song L
    J Bone Miner Metab; 2018 Sep; 36(5):560-572. PubMed ID: 29124436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological function of bone cells on the PTH-driven anabolic effect].
    Hasegawa T; Hongo H; Sasaki M; Yamada T; Amizuka N
    Clin Calcium; 2012 Mar; 22(3):373-9. PubMed ID: 22370304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone histology after intermittent PTH treatment - animal models -].
    Sasaki M; Hasegawa T; Hongo H; Yamamoto T; Amizuka N
    Clin Calcium; 2013 Mar; 23(3):347-53. PubMed ID: 23445886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects.
    Yao W; Cheng Z; Shahnazari M; Dai W; Johnson ML; Lane NE
    J Bone Miner Res; 2010 Feb; 25(2):190-9. PubMed ID: 19594295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts.
    Li X; Qin L; Bergenstock M; Bevelock LM; Novack DV; Partridge NC
    J Biol Chem; 2007 Nov; 282(45):33098-106. PubMed ID: 17690108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.
    Li C; Xing Q; Yu B; Xie H; Wang W; Shi C; Crane JL; Cao X; Wan M
    J Bone Miner Res; 2013 Oct; 28(10):2094-108. PubMed ID: 23609180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory leukocyte protease inhibitor promotes differentiation and mineralization of MC3T3-E1 preosteoblasts on a titanium surface.
    Choi BD; Lee SY; Jeong SJ; Lim DS; Cha HJ; Chung WG; Jeong MJ
    Mol Med Rep; 2016 Aug; 14(2):1241-6. PubMed ID: 27279420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
    Yu X; Schøller J; Foged NT
    Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17/N-cadherin mediated disruption of PTHR1/LRP-6 interaction.
    Mansoori MN; Shukla P; Singh D
    Bone; 2017 Dec; 105():226-236. PubMed ID: 28935557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propranolol Promotes Bone Formation and Limits Resorption Through Novel Mechanisms During Anabolic Parathyroid Hormone Treatment in Female C57BL/6J Mice.
    Treyball A; Bergeron AC; Brooks DJ; Langlais AL; Hashmi H; Nagano K; Barlow D; Neilson RJ; Roy TA; Nevola KT; Houseknecht KL; Baron R; Bouxsein ML; Guntur AR; Motyl KJ
    J Bone Miner Res; 2022 May; 37(5):954-971. PubMed ID: 35122666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.